Merck data at the ash 2024 annual meeting highlights promising hematology pipeline with diverse range of investigational assets and novel modalities

Rahway, n.j.--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside of the united states and canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the american society of hematology (ash) annual meeting and exposition in san diego from dec. 7-10. data being shared at the meeting will showcase the company's continued progress in advancing clinical research for merck's expanding and diverse pipeline of inv.
ASH Ratings Summary
ASH Quant Ranking